growth strategi full swing
come
believ agil result manag top alreadi high expect
quarter best appear still come broad base strength
quarter help give us convict agil commerci strategi
compel cadenc new product reson custom coincid
outsiz exposur healthi end market highlight
organ growth show continu momentum top alreadi robust result
peer growth remark broad-bas core growth life scienc
appli lsag growth cross lab acg growth diagnost dgg
end market grew least mid single-digit reassur see
two largest end market lead pack chemic energi
biopharma agil leverag top-lin growth healthi margin expans
y/i drive ebitda growth y/i
agil rais guidanc continu view outlook
conserv due sever factor first end market condit remain robust
agil differenti exposur biopharma manufactur chemic energi
allow out-grow peer second point organ growth guidanc
increas line beat ceo mike mcmullen note
embed conservat continu take quarter-by-quart look
busi stand readi rais full year guidanc busi condit remain
favor third new product begin reson market
drive better revenu growth margin expans compani agil
highlight earli success intuvo gc ultivo lc/m platform fourth
continu see substanti opportun agil term capit deploy
agil gain access billion trap oversea cash repatri
compani prefer toward although share repurchas also repres
attract use capit continu believ agil differenti
growth profil warrant differenti valuat multipl reiter
overweight rate rais price
quarterli annual ep usd
consensu number thomson reuter
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
rais usd
return equiti ttm
link barclay live interact chart
overweight agil built strong track
record reput oper perform
develop divers portfolio busi
across instrument diagnost favor
agil exposur growth biopharma
rev new product cycl ga chromatographi
opportun repatri drive upsid
improv growth chemic energi end
market due stabil trend gc product
cycl could lead better growth capit alloc
also remain opportun upsid case
reflect upsid ebitda billion
agil exposur econom activ end
market could impact growth downsid
case reflect downsid ebitda
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
believ agil result manag top alreadi high expect
quarter best appear still come broad base strength quarter
help give us convict agil commerci strategi compel cadenc
new product reson custom coincid outsiz exposur
healthi end market highlight organ growth show continu
momentum top alreadi robust result peer growth remark broad-
base core growth life scienc appli lsag growth cross lab
acg growth diagnost dgg end market grew least mid
single-digit reassur see two largest end market lead pack
chemic energi biopharma agil leverag top-lin growth
healthi margin expans y/i drive ebitda growth y/i
agil rais guidanc continu view outlook
conserv due sever factor first end market condit remain robust
agil differenti exposur biopharma manufactur chemic energi
allow out-grow peer second point organ growth guidanc
increas line beat ceo mike mcmullen note
embed conservat continu take quarter-by-quart look busi
stand readi rais full year guidanc busi condit remain favor
third new product begin reson market drive better
revenu growth margin expans compani agil highlight earli success
intuvo gc ultivo lc/m platform fourth continu see
substanti opportun agil term capit deploy agil gain access
billion trap oversea cash repatri compani prefer
toward though share repurchas also repres attract use capit
continu believ agil differenti growth profil warrant differenti
valuat multipl reiter overweight rate
rais price target price repres
adj ebitda forecast billion prior price repres
prior adj ebitda forecast billion
strong result agil rais revenu ep guidanc although
continu believ compani outlook emb conservat revenu
expect rang billion emb organ
growth acquisit contribut fx midpoint
revenu guidanc rais million organ growth expect
increas roughli agil comfort end market dynam
short-term compani continu cautiou mid- long-term view
end market fundament last quarter agil issu expect growth
end market includ growth diagnost clinic growth chemic
growth biopharma environment forens
academ govern start year compani track well ahead
forecast academ govern environment forens chemic
ep expect rang midpoint guidanc
oper margin expect repres expans y/i
repres signific deceler prior year
although note upsid compani organ growth guidanc
would like drive signific margin leverag compani
million million complet repurchas fall within two
tranch first million share use off-set dilut
includ compani assumpt million share count remain
amount would repres upsid compani forecast agil anticip non-gaap
tax rate interest expens million
agil forecast revenu billion impli organ
growth ep revenu growth expect
addit organ growth emb acquisit fx
weaker expect rel result difficult
comp lunar new year fall second quarter versu first
stabil believ recov industri end market continu
repres opportun agil chemic segment repres
roughli compani total revenu within segment revenu split amongst
chemic custom refin compani year
lead weak spend end market creat drag
growth agil life scienc tool group said agil chemic
busi recov grow heel better spend across
custom base strength continu segment grew strong
result product categori compani note chemic benefit
improv market condit well new product call manag
increas guidanc end market although comp
less favor believ sustain level spend amongst chemic energi
compani could contribut increment upsid agil
recent pmi trend remain healthi expansionari territori believ provid
quarter visibl result januari composit pmi
ism regist europ manufactur pmi markit regist
china remain solid beyond improv pmi perform view china
attract end market life scienc tool compani given countri invest
area well-align coverag notabl biopharmaceut life scienc
research well higher environment standard
see signific correl agil organ growth tracker
compani blend geographi barclay agil pmi tracker regist
q/q approxim agil revenu gener outsid
unit state exposur asia europ compani
barclay agil pmi end market tracker one-quart lead correl
compani organ growth rate notic trend agil
geograph exposur growth past quarter far back intern
data track believ pmi tracker best use one-quart lead
indic expansionari tracker perform start year give us good
convict agil abil hit initi guidanc organ
follow complet earn consensu estim call
continu recoveri capital-expenditure given import capit spend
compani busi model see spend forecast reliabl addit
direct correl due lt contract nuanc believ upstream
spend look lead indic downstream spend
integr oil compani capital-expenditure tracker suggest spend turn posit
growth spend expect improv integr oil
compani exposur across entir energi suppli chain believ act
good proxi entir energi end market spend life scienc tool integr
oil compani less lean compar compani focu one piec
suppli chain creat lag perform spend market dynam
improv addit integr oil compani downstream exposur mean
market dynam would favor upstream player
 consist apc eca nfx compani cover barclay analyst
tom driscol estim base compani guidanc base thomsonon consensu estim
intern integr oil consist cve hse imo pbr su cover barclay analyst paul cheng bp nest omv rdsa
fp cover barclay analyst lydia rainforth rdsa pbr base barclay estim other base consensu
commod price recent stabil creat favor environ
life scienc tool custom industri end market track price
commod gain real-tim perspect dynam within energi
chemic market price oil ultim impact entir energi suppli
chain compani downstream refin compani direct exposur
price oil capit invest guidanc help spend longer-
term ultim depend commod price compani downstream energi
suppli chain affect well howev less direct weak seen
price oil dramat effect capit spend energi industri
repres headwind life scienc tool
rig count import indic supply/demand also give us
idea energi cycl lower rig count lead lower suppli
thu higher commod price assum stabl demand improv profit
energi compani compani spend profit capit invest fuel
addit product far remov trough level rig market
mean energi compani begin spend bring capac back on-line
recent baker hugh bhge count februari read
 intern januari read y/i
believ agil new product launch drive financi impact
replac cycl excess growth rel peer upsid case believ
combin product launch could add overal organ
new product cadenc agil
agil new product cycl ga chromatographi repres sustain
opportun revenu growth estim gc million busi
agil approxim rev specif agil launch intuvo
two summer ago consid revolutionari matur ga
chromatographi market agil began develop instrument six year ago
custom need mind relat demand smaller size better energi consumpt
eas use notabl intuvo approxim third footprint
older model enabl better lab util addit instrument
oper lab technician minim train big adjust rel
older model column trim remov impur manual requir
skill oper intuvo autom column replac attract
lab struggl find talent lab technician
manag optimist earli feedback relat introduct
instrument ceo mike mcmullin note earn start
see repeat order multi-unit purchas intuvo cg particularli high
throughput applic theyr often use mass spec play
thought would despit posit feedback manag note
septemb launch mani custom opportun
account purchas budget said manag confid
custom factor futur intuvo purchas budget
excit surround intuvo custom also show increas
interest agil ga chromatographi instrument
agil see intuvo long term benefit compani gc
opportun agil sizabl total address market excess
billion penetr time addit instrument sale launch also
present opportun agil drive better consum revenu growth
intuvo sell around premium older gc instrument
compani expect roughli user bundl intuvo mass
spectrometri instrument sell approxim estim agil
larger next biggest player shimadzu instrument revenu account
million consum servic compris rest much roughli
instal base outliv year product life cycl longer
elig support introduct intuvo well time agil
opportun add share market readi major upgrad
cycl follow prolong weak chemic end market said
market size bn agil posit intuvo august price premium consum additiondemo unitslaunch underwaylc/m junedemo unitslaunch underwayoligo demand capac line clinic multiplicom acquisit lasergen investmentpopgen ip portfolio acquisitionfin lasergen payment year post lasergen invest barclay agil
would caution earli new product launch would expect
improv sale increment rather overnight fact
compani believ replac cycl stretch year follow
shape normal curv
instrument good exampl ceo mike mcmullen help guid
innov way help drive stickier revenu stream longer term
exampl chang chromatographi column compani develop
technolog protect column contamin guard work seamlessli
high-touch interact consum agil ip
compani believ feed nice consum stream compani
expect lab purchas consum stream instrument includ
instrument autom tool sampl prep capabl believ consum
could repres revenu per instrument
gc market tam agil million
 launch asm agil ultivo lc/m describ ceo mike
mcmullen revolutionari compani newest lc/m triple-quad featur
smaller footprint improv workflow custom system design
routin work environ insid research lab agil view
sweet spot drive adopt sale specif compani expect strong
util environment food arena rel gc opportun lc
opportun bigger market agil smaller market share
system launch began ship novemb expect
begin make impact given time capit budget decis patrick
kaltenbach agil presid lsag note earn realli
pleas accept field custom get excel
feedback first instal drive lot excit
product portfolio drive ultivo volum also drive lot
collater busi us lc/m busi
 agil add addit capac oligonucleotid activ pharmaceut
ingredi api manufactur busi start million
facil full capac growth busi depend complet
agil new facil fredrick co view attract busi
compani agil estim new facil wont oper end
clearli long-term opportun upon complet new facil
abl immedi meet million demand futur expans increas
potenti million servic line commerci oligo-
base therapi market today agil current busi servic custom
millionslow -- -- footprint instrument player gc instrument asp purchas today ms instrument asp per rang life gc year consum barclay agil
clinic research phase develop view follow complet
fredrick facil prospect busi depend commerci
success therapi
agil patholog busi compani invest autom
omni pay double-digit growth addit compani
see nice adopt companion diagnost assay nsclc
compani innov acquir genom side piec togeth
clinic genom workflow strategi last year featur
pick-up sureselect sampl prep multiplicom target enrich popgen
acquisit ip allow agil barcod back-end solut
cartagenia term sequenc compani want integr
solut made invest lasergen although hasnt rule
suppli agreement competitor agil believ channel
custom relat success market longer term
follow organ declin biopharma custom
encourag see compani return strength post organ
growth strength biopharma driven broad-bas growth across instrument
consum servic well larg small molecul custom compani
total biopharma exposur estim expos larg molecul small
molecul quarter appear agil biopharma busi benefit
push million revenu despit benefit end
market would grown mid single-digit line compani longer-
organ growth biopharma end market calendar quarter
tool averag includ agil thermo fisher
chemic end market strong fourth consecut quarter
organ growth y/i strength driven broad base growth across region
product sub-seg agil larg number custom across six primari
end market pharma revenu academ govern
food except clinic diagnost y/i everi end
market outperform expect quarter beyond biopharma chemic
 academ govern y/i environment forens y/i
food y/i strong contributor growth quarter academ
govern end market driven strength china europ environment
forens benefit solid growth forens well gc gc/m icp/m
strength environment growth food end market driven consum ms
gc geograph strength europ patholog cdx franchis continu
driver clinic diagnost end market
revenu percentag industri segment
organ revenu growth quarter strong growth
compani three segment life scienc appli market busi rev
grew organ y/i tailwind fx agil crosslab group
rev grew organ revenu y/i tailwind fx final
diagnost genom group revenu grew y/i organ
headwind fx
compani post anoth quarter strong growth china remain
optimist outlook despit increasingli difficult comp manag
see sign slowdown china quarter agil grew high-
revenu percentag geographi
teen china addit compani excit recent launch valu line
consum china high single-digit growth expect china
quarter europ america grew high-singl digit
gross margin increas y/i look sub-seg life
scienc appli improv y/i diagnost genom declin y/i
crosslab improv y/i revenu adjust ebit margin
improv y/i rel expect upsid came better oper
margin life scienc appli crosslab life scienc appli margin
came estim crosslab margin came
expect altern oper margin dgg
estim
gross margin oper margin trend
percentag revenu sg expens expect
expens ex-stock base comp revenu
expect y/i sg ex-stock base comp
expect y/i compani remain focus agil agil
cost save initi includ seri oper program view
primari driver leverag cost item go organ growth
 sg trend ex-stock base comp
cffo million quarter agil repurchas million share
deduct million capital-expenditure free cash flow million quarter total
agil return million sharehold dividend posit
agil rais cffo guidanc billion million
continu model capital-expenditure million recent rais dividend agil
forecast return million dividend addit compani million
remain share repurchas author would expect agil
opportunist throughout year
agil mm except ep reportedincom profit ebitda ebit pre-tax pre-tax tax net net researchprior yearprior quarter barclay agil
meehan cfa herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli relat
specif recommend view express research report
